Expert Consensus on the Clinical Application of PI3K/AKT/mTOR Inhibitors in the Treatment of Breast Cancer (2025 Edition)
Updates to the consensus include the introduction of newly approved PAM pathway inhibitors, updated data from recent clinical trials, and expanded therapeutic applications. The revised guidance also offers updated recommendations for genetic testing to detect alterations in relevant pathways. The section on managing drug-related adverse events has been significantly expanded, providing detailed insights into different types of adverse events and their management. These updates aim to enhance the clinical application of PAM pathway inhibitors, promote precision medicine, and ultimately, improve survival outcomes for patients with breast cancer.
Publication Details
- Journal
- Cancer Innovation
- Published
- 2025-04-09
- DOI
- https://doi.org/10.1002/cai2.70008
- Citations
- 5
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 7.59
Funders
- Yale University
- Clinical Trial Center, China Medical University Hospital
- Harbin Medical University
- Peking University First Hospital
- Chinese Academy of Sciences
- Sun Yat-sen University
- Fudan University
- Chongqing Medical University
- Chinese Academy of Medical Sciences
- China Medical University
- Peking University
- Hebei University
- Peking Union Medical College Hospital
- General Hospital of People’s Liberation Army
- Tianjin Medical University
- Qinghai University
- Peking Union Medical College
- Qingdao University
- Fujian Medical University
- Peking University People's Hospital
- Guangdong Provincial People's Hospital
- Sun Yat-sen University Cancer Center